These results demonstrate that the presence of polymorphism in IL6R, regardless of the usual cardiovascular disease risk factors, is caused by a dose-dependent lowering in the accumulation of CRP and fibrinogen and, essentially, lower CHD risk, most likely by reducing the inflammatory response. The gene discussed is CRP; the disease is coronary artery disorder.